July 2010
 

XVIII International AIDS Conference Citations

POSTER Maraviroc in treatment-experienced patients G. Sterrantino, M. Trotta, P.G. Rogasi, et al PDF Poster     Abstract POSTER Duration of antiretroviral regimens including Raltegravir, Maraviroc, Darunavir and/or Etravirine in clinical practice I. Castillo Romera, A. Ais Larisgoitia, V. Escudero Vilaplana, et al PDF Poster    Abstract POSTER Low risk of malignancy with maraviroc in treatment-experienced (TE) and treatment-naïve (TN) patients across the maraviroc clinical development program S. Walmsley, R. Campo, J. Goodrich, et al PDF Poster     Abstract POSTER Duration of antiretroviral regimens including Raltegravir, Maraviroc, Darunavir and/or Etravirine in clinical practice I. Castillo Romera, A. Ais Larisgoitia, V. Escudero Vilaplana, et al PDF Poster    Abstract POSTER Efficacy and safety of MVC in treatment-experienced over-sixty patients G. Sterrantino, B. Borchi, M. Trotta, et al PDF Poster     Abstract POSTER Virologic outcome by V3 loop genotypic population sequencing and 454 'deep sequencing' in clade B and non-B virus in MERIT at 48 and 96 weeks S. Portsmouth1, D. Chapman1, M. Lewis, et al PDF Poster     Abstract POSTER Use of genotypic and maraviroc (MVC) clinical trial data to develop statistical models for predicting r esponse in a treatment-experienced (TE) population P. Biswas, D. Chapman, X. Zhong, et al PDF Poster     Abstract POSTER Effect of 24 weeks intensificaction with a CCR5-antagonist on the decay of the HIV-1 latent reservoir L. Díaz, C. Gutierrez, C. Page, et al PDF Poster    Abstract POSTER Effect of a CCR5 antagonist in immune activation in highly suppressed HIV-1 infected patients A. Vallejo1, L. Diaz, M. Abad, et al PDF Poster     Abstract Maraviroc containing regimen suppress cerebrospinal fluid HIV replication in HIV-1 infected patients with neurological symptoms G. Melica, A. Canestri, G. Peytavin, et al Clinical outcome of HIV tropism testing and Maraviroc regimens - 48 weeks follow-up H. Knechten, F. Wiesmann, E. Wolf, et al Hard rescue: prospective study of effectiveness and safety of new drugs (Darunavir-DRV, Etravirina-ETR, Raltegravir-RTG andMaraviroc-MVC) in the last four years (2006-2009) H. Azkune Galparsoro,.A. Iribarren Loyarte, M.J. Aramburu Bengoechea, et al In vivo synergistic activity of maraviroc and raltegravir in the reduction of HIV proviral burden in circulating reservoirs C. Tommasi, E. Nicastri, I. Abbate, et al mDAPTA, a potent CCR5 receptor blocker, prevents viral recovery from CD8-depleted patient PBMCs with VL< 50 background L. Agrawal, O. Ducoudret, N. Baichoo, et al Detection of CXCR4-using variants in circulating and proviral HIV quasispecies from patients treated with CCR5 antagonist by ultra-deep pyrosequencing I. Abbate, G. Rozera, C. Tommasi, et al Maternal-fetal pharmacokinetics of a single intrapartum dose of maraviroc in rhesus macaques M. Winters1,, K. Van Rompay, A. Kashuba,,et al Safety and immunovirological activity of once daily maraviroc (MVC) in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine 200mg/tenofovir 300mg QD (TDF/FTC) + ATV/r in treatment-naïve patients infected with CCR5-tropic HIV-1 (Study A4001078): A week 24 planned interim analysis A. Mills, D. Mildvan, D. Podzamczer, et al

Journal Citations

• A WEEK-IN-REVIEW FEATURED REPORT
  Long-Term Immunovirogical Effect And Tolerability Of A Maraviroc-Containing Regimen
  In Routine Clinical Practice.
  Genebat M, Ruiz-Mateos E, Pulido I, et al Curr HIV Res. 2010 Jul 20
• A WEEK-IN-REVIEW FEATURED REPORT
  Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients
  with neurological symptoms.
  Melica G, Canestri A, Peytavin G, et al AIDS. 2010 Jul 1